- NEWS AND VIEWS
Blocking cell death limits lung damage and inflammation from influenza
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 628, 726-727 (2024)
doi: https://doi.org/10.1038/d41586-024-00910-2
References
Gautam, A. et al. Nature 628, 835–843 (2024).
Flerlage, T., Boyd, D. F., Meliopoulos, V., Thomas, P. G. & Schultz-Cherry, S. Nature Rev. Microbiol. 19, 425–441 (2021).
Nogusa, S. et al. Cell Host Microbe 20, 13–24 (2016).
Mandal, P. et al. Mol. Cell 56, 481–495 (2014).
Newton, K. et al. Science 343, 1357–1360 (2014).
Sanders, C. J. et al. Am. J. Physiol. Lung Cell. Mol. Physiol. 304, L481–L488 (2013).
Bantia, S. et al. Antimicrob. Agents Chemother. 45, 1162–1167 (2001).
Leyva-Grado, V. H. & Palese, P. Antivir. Res. 142, 12–15 (2017).
Pierotti, C. L. & Silke, J. Immunol. Cell Biol. 100, 79–82 (2022).
Bader, S. M. et al. Cell Death Dis. 15, 100 (2024).
Competing Interests
Anaxis, a company developing necroptosis inhibitors, supports a position in the J.S. laboratory.